Opendata, web and dolomites

3DCC

Ready-to-use 3D Cell Cultures for early de-risking in drug development

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 3DCC project word cloud

Explore the words cloud of the 3DCC project. It provides you a very rough idea of what is the project "3DCC" about.

facilities    progress    eliminate    big    populations    tissue    opportunity    programs    economies    company    enriched    thanks    biological    efficacy    800    profile    report    customers    clinical    integration    markets    stem    ready    cultures    unacceptable    million    buy    models    candidate    latest    culture    competitive    establishes    niches    pharmaceutical    drug    media    successfully    supply    usd    sera    cancer    broad    3d    bcc    pharma    expensive    pipeline       capitalizing    cell    fail    csc    compounds    industry    global    120    biopharmaceutical    trials    treatment    disposable    2016    23    kits    96    market    plate    2021    clear    compatibility    manually    strategy    stemtek    37    cagr    lack    466    seven    precisely    assays    made    standard    largely    thriving    spheroid    solution    reagents    345    tailor    enter    3dcc    10    format    advantages    business    effect    drugs    appears    commodity    companies    toxicity   

Project "3DCC" data sheet

The following table provides information about the project.

Coordinator
STEMTEK THERAPEUTICS SL 

Organization address
address: KABI 612 LABORATORIO 17 ASTONDO BIDEA S/N PARQUE TECHNOLOGICO Y CIENTIFICO DE BIZKAIA
city: DERIO
postcode: 48160
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://www.stemtektherapeutics.com/en/cell2sphere-kit
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STEMTEK THERAPEUTICS SL ES (DERIO) coordinator 50˙000.00

Map

 Project objective

StemTek is a global biopharmaceutical company with a clear stem cell focus in drug development for cancer treatment. Only about 10% of the candidate compounds progress successfully through clinical development. Many drugs fail during clinical trials, especially during phase III, which is the most expensive phase of clinical development, largely due to the lack of clinical efficacy and/or unacceptable toxicity.

StemTek is developing a solution to make cell based assays a commodity: easy to get, easy to buy, easy to use, and disposable, so we eliminate the need for large tissue culture facilities. This new solution is a ready-to-use 3D spheroid culture in standard 96 well plate format that allows customers to profile their pipeline of compounds for their effect on CSC populations using 3D culture models.

Thanks to the 3DCC, a business opportunity appears to develop a multi-million euro business capitalizing on the thriving interest from Pharma in finding novel biological testing systems based on 3D cell culture. Latest Markets&market report (2016) establishes that the global 3D cell culture market is expected to reach USD 1,345.2 M by 2021 from USD 466.8 M in 2016 at a CAGR of 23.6% (market growth). According to BCC research, from the seven different niches, “Reagents, media and sera” is precisely the most relevant (37.2 %). 3DCC objectives are: • To produce tailor made kits to improve compatibility with different drug development programs, leading to a broad range of applications. • To use all the competitive advantages of CSC enriched 3D spheroid cultures in ready to use standard 96 well plate format. • The large-scale production of ready to use kits to be able to enter/supply the pharmaceutical industry to achieve economies of scale, and go from current 800 kits/year (manually) up to 120.000 kits per year. • The integration of CSC testing into the drug development strategy of top 10 Big Pharma companies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3DCC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3DCC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More